US4061779A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Naphthalene derivatives having anti-inflammatory activity
Assignee: Beecham Group PLC
•
Filing: 1976-12-08
•
Granted: 1977-12-06
•
Expires: 1996-12-08
Abstract
Abstract 4-(6'-Methoxy-2'-naphthyl) butan-2-one is described as having anti-inflammatory activity and an improved therapeutic ratio.
Inventors
- 👤 Anthony William Lake
- 👤 Carl John Rose
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 18:11
CPC Classifications
C; C07; C07C; C07C29/00; C07C29/132; C07C29/136; C07C29/143; C07C29/145; C07C29/36; C07C29/38; C07C29/40; C07C43/00; C07C43/02; C07C43/20; C07C43/23; C07C45/00; C07C45/26; C07C45/45; C07C45/46; C07C45/61; C07C45/62; C07C45/67; C07C45/68; C07C45/72; C07C45/74; C07C49/00; C07C49/20; C07C49/255; C07C59/00; C07C59/40; C07C59/58; C07C59/64; C07C2602/00; C07C2602/02; C07C2602/14; C07C2602/26
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
29 words
A pharmaceutical composition useful for treating inflammation in humans which comprises an anti-inflammatory effective amount of the compound of the formula: ##STR26## in combination with a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
29 words
A pharmaceutical composition useful for treating inflammation in humans which comprises an anti-inflammatory effective amount of the compound of the formula: ##STR26## in combination with a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
11 words
A pharmaceutical composition according to claim 1 in oral administration form.
Claim 4
Dependent Claim
31 words
A pharmaceutical composition according to claim 1 in unit dose form for oral administration to humans which comprises from 20 mg to 1000 mg of a compound of the formula: ##STR27##
Claim 5
Dependent Claim
27 words
A pharmaceutical composition according to claim 3 in tablet or capsule form which comprises from 100 mg to 600 mg of a compound of the formula: ##STR28##
Claim 6
Dependent Claim
34 words
A pharmaceutical composition useful for the treatment of rheumatic and arthritic conditions in humans which comprises a therapeutically effective amount of a compound of the formula ##STR29## in combination with a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
34 words
A pharmaceutical composition useful for the treatment of rheumatic and arthritic conditions in humans which comprises a therapeutically effective amount of a compound of the formula ##STR29## in combination with a pharmaceutically acceptable carrier.
Claim 8
Dependent Claim
11 words
A pharmaceutical composition according to claim 5 in oral administration form.
Claim 9
Dependent Claim
35 words
A method of reducing inflammation in humans which comprises administering to a human in need thereof an amount of a composition of claim 1 sufficient to produce an anti-inflammatory effect without an undesired oestrogenic effect.
Claim 10
Dependent Claim
12 words
A method according to claim 7 wherein the composition is administered orally.
Claim 11
Dependent Claim
34 words
A method according to claim 8 wherein the composition is in the form of a unit dose for oral administration wherein each unit dose contains from 20 mg to 1000 mg of said compound.
Claim 12
Dependent Claim
34 words
A method according to claim 8 wherein the composition is in the form of a unit dose for oral administration wherein each unit dose contains from 100 mg to 600 mg of the compound.
Claim 13
Dependent Claim
39 words
A method of treating rheumatic and arthritic conditions in humans which comprises administering to a human in need thereof an amount of a composition of claim 5 sufficient to provide relief from the rheumatic or arthritic condition being treated.
Claim 14
Dependent Claim
12 words
A method according to claim 11 wherein the composition is administered orally.
Claim 15
Dependent Claim
12 words
Solid 4-(6'-methoxy-2'-naphthyl)butan-2-one hving a melting poit of not less than 78.5° C.
Claim 16
Dependent Claim
12 words
Solid 4-(6'-methoxy-2'-naphthyl)butan-2-one hving a melting poit of not less than 78.5° C.
References Cited (Backward Citations)
US3880932A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-12-05 | 1981-06-06 | 1981-12-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-12-05 | 1985-06-06 | 1985-12-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-12-05 | 1989-06-06 | 1989-12-06 | $7700.00 | Window Closed / Lapsed |